Clinical Trial Update: Capecitabine For Nasopharyngeal Cancer [Phase 2]

View source ↗

Summary

Phase 2 clinical trial of capecitabine for nasopharyngeal carcinoma has completed, with Dana-Farber Cancer Institute listed as sponsor.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Head and Neck Cancer
• Nasopharyngeal Carcinoma

Drugs mentioned

• Capecitabine (capecitabine)

Snippet

Sponsor: Dana-Farber Cancer Institute | Conditions: Head and Neck Cancer | Phase 2 | Status: COMPLETED